Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.
Curr Treat Options Cardiovasc Med
; 20(2): 18, 2018 Mar 01.
Article
em En
| MEDLINE
| ID: mdl-29497862
ABSTRACT
PURPOSE OF REVIEW BRCA1 and BRCA2 mutation carriers can be at increased cardiovascular risk. The goal of this review is to provide information about factors associated with increased cardiovascular risk, methods to prevent cardiovascular toxicities, and recommended screening guidelines. RECENT FINDINGS:
BRCA1/2 mutation carriers who are diagnosed with cancer are often exposed to chemotherapy, chest radiotherapy, and/or HER2 directed therapies, all of which can be cardiotoxic. In addition, BRCA1/2 carriers often undergo prophylactic salpingoopherectomies, which may also increase cardiovascular risks. Understanding the potential for increased cardiovascular risk in individuals with a BRCA1 or BRCA2 mutation, as well as gold standard practices for prevention, detection, and treatment of cardiac concerns in this population, is important.
Texto completo:
1
Bases de dados:
MEDLINE
Tipo de estudo:
Guideline
Idioma:
En
Revista:
Curr Treat Options Cardiovasc Med
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Estados Unidos